Enrichment of patients with concomitant limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) on the Alzheimer's disease continuum using hippocampal volume
Authors:
- Nidhi S. MundadaNMNidhi S. Mundada
- David A. WolkDWDavid A. Wolk
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
Open Access
- 13 December 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (12) , e70970
Abstract
INTRODUCTION: Clinical overlap between Alzheimer's disease (AD) and limbic‐predominant age‐related transactive response DNA binding protein 43 (TDP‐43) encephalopathy (LATE), combined with the absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut‐off and examined associated atrophy and cognitive profiles. METHODS: We studied cognitively impaired (CI) Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with T1‐magnetic resonance imaging (MRI) and amyloid‐ and tau‐positron emission tomography (PET). Participants were classified into suspected (s) AD+sLATE−, AD−sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole‐brain atrophy patterns and cognitive profiles were compared cross‐sectionally and longitudinally. Classification was validated in an autopsy cohort. RESULTS: AD+sLATE+ showed greater anterior hippocampal (AH) and amygdala atrophy than AD+sLATE−. AD−sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. DISCUSSION: A simple HV quartile cut‐off may help identify mixed AD/LATE pathology and support clinical trial enrichment. Highlights: Quartiles of HVs stratify CI individuals. Approach distinguishes suspected AD+sLATE–, AD–sLATE+, and AD+sLATE+ subgroups. The method is simple, scalable, and requires no complex modeling or biomarker panels. It enables practical identification of mixed pathology in clinical settings. It supports trial enrichment by excluding or targeting mixed pathology cases.Keywords
Funding Information
- National Institutes of Health (P30‐AG072979)
- National Institutes of Health (RF1‐AG069474)
- National Institutes of Health (R01‐AG056014)
- National Institutes of Health (R01‐AG072796)
- Alzheimer's Disease Neuroimaging Initiative
- National Institute on Aging (U19 AG024904)
This publication has 55 references indexed in Scilit:
- Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurementsNeuroImage, 2014
- TDP-43 is a key player in the clinical features associated with Alzheimer’s diseaseActa Neuropathologica, 2014
- Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification MethodsJournal of Nuclear Medicine, 2012
- FSLNeuroImage, 2012
- Regression-based label fusion for multi-atlas segmentation2011
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Registration based cortical thickness measurementNeuroImage, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inferenceNeuroImage, 2009
- Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brainMedical Image Analysis, 2008